Background: Axial spondyloarthritis (axSpA) is characterized by coexisting bone loss and pathological new bone formation. Although alterations in circulating markers and osteoclastogenesis from peripheral blood monocytes (PBM) are documented in radiographic axSpA (r-axSpA), their status in non-radiographic axSpA (nr-axSpA) and association with bone loss remain unresolved. In this study, we evaluated serum markers of bone metabolism and inflammation, PBM osteoclastogenic capacity, and their association with bone mineral density across both axSpA phenotypes. Methods: In 81 axSpA patients, clinical characteristics and DEXA-based BMD were recorded. Serum TSH, PTH, 25(OH)D3, bCTX, PINP, osteocalcin, bALP, RANKL, OPG, CTSK, CRP, IL-6 and IL-17 were measured. PBM from a patient subset (N=26) were used for in vitro osteoclastogenesis assays. Results: In a multivariable model, femoral neck Z-scores were strongly negatively associated with serum OPG/RANKL ratio in males (48% OPG/RANKL increase per one-unit Z-score decrease, p< 0.01). Additionally, each one-unit decrease in femoral neck Z-score was associated with increased odds of r-axSpA (OR 1.96, p< 0.05), independently of OPG/RANKL. Though patients with r-axSpA had lower femoral neck Z-scores than nr-axSpA (mean −0.50 vs. 0.03, p< 0.05), their in vitro osteoclastogenesis did not differ significantly (median 21 vs. 40, p=NS). Instead, osteoclastogenesis associated with BMD, being lower in patients with reduced femoral neck BMD compared to normal BMD (mean 22 vs. 51, p< 0.05). Conclusions: This study highlights the femoral neck as a region of interest for studying bone loss in nr-axSpA and r-axSpA and supports a link between systemic bone loss, circulating OPG/RANKL levels, and precursor osteoclastogenic potential in axSpA.